Amoeba Protects Kids from Deadly C. Difficile Infections
The funds will support his effort to engineer an amoeba - a single-celled organism - to deliver antibodies that can prevent and treat potentially deadly C. difficile infections in young…
Browsing Tag
Cystic fibrosis
$179.34 Million by 2028, OPEP (Oscillating Positive Expiratory Pressure) Devices…
New York, May 10, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Oscillating Positive Expiratory Pressure (OPEP) Devices Market Forecast to 2028 –…
Experimental Drug may Prove Beneficial Against Life-threatening Respiratory Diseases
Potentially fatal conditions arising from an uncontrolled secretion of mucins in the airways like asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF), as well as…
Study Shows Why Some Respiratory Infections Persist Despite Proper Treatments
The results highlight the need to consider the interaction between different species of microbe when treating infections with antibiotics -- and to adjust dosage accordingly.
…
Antibiotics’ Effectiveness Decreases When Multiple Bugs Present
"People with chronic infections often have co-infection with several pathogens, but the problem is we don't take that into account in deciding how much of a particular antibiotic to treat…
Proteins That may Influence Cystic Fibrosis Discovered
"We identified more than 400 proteins associated with either healthy or mutant CFTR, and have shown that some of them could predict the variability seen in patient symptoms and treatment…
Cystic Fibrosis Pipeline Offers Promising New Options for Treatment | DelveInsight
Las Vegas, USA, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Cystic Fibrosis Pipeline Offers Promising New Options for Treatment | DelveInsight The Cystic Fibrosis (CF) therapeutic development…
ContraFect Announces Award from the Cystic Fibrosis Foundation to Evaluate Exebacase…
YONKERS, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct…
Aceragen’s wholly-owned subsidiary, Arrevus, awarded $45 million funding agreement…
Raleigh-Durham, NC, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Arrevus, Inc., a clinical-stage biopharmaceutical company developing therapies for orphan infectious diseases with high unmet…
EnBiotix, Inc. Closes $11M Pre-Merger Financing
BOSTON, Dec. 29, 2021 (GLOBE NEWSWIRE) -- EnBiotix, Inc., a rare disease company currently focused on chronic respiratory disorders, today announced the closing of an $11M pre-merger,…